Differential activation of cord blood and peripheral blood natural killer cells by cytokines

Cytotherapy

Volumn 17, Issue 1, 2015, Pages 73-85

  Alnabhan, Rehab ^a,b   Madrigal, Alejandro ^a,b   Saudemont, Aurore ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ANTHONY NOLAN RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Cord blood; Cytokine activation; Memory like NK cells; Natural killer cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; STAT5 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UMBILICAL CORD BLOOD; CYTOLOGY; FETUS BLOOD; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; UMBILICAL CORD;

CYTOKINES; FETAL BLOOD; HEMATOPOIETIC STEM CELLS; HUMANS; KILLER CELLS, NATURAL; PHENOTYPE; UMBILICAL CORD;

EID: 84927125324     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.08.003     Document Type: Article

References (64)

1. Caligiuri M.A. Human natural killer cells. Blood 2008, 112(3):461-469.
2. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat Immunol 2008, 9(5):503-510. 10.1038/ni1582.
3. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23(1):225-274.
4. Burns L.J., Weisdorf D.J., DeFor T.E., Vesole D.H., Repka T.L., Blazar B.R., et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant 2003, 32(2):177-186.
5. Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Leitman S., et al. Aprogress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. NEngl J Med 1987, 316(15):889-897.
6. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295(5562):2097-2100.
7. Ruggeri L., Mancusi A., Capanni M., Martelli M.F., Velardi A. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005, 17(2):211-217.
8. Barkholt L., Alici E., Conrad R., Sutlu T., Gilljam M., Stellan B., et al. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study. Immunotherapy 2009, 1(5):753-764.
9. Iliopoulou E., Kountourakis P., Karamouzis M., Doufexis D., Ardavanis A., Baxevanis C., et al. Aphase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010, 59(12):1781-1789.
10. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105(8):3051-3057.
11. Gluckman E., Rocha V. Donor selection for unrelated cord blood transplants. Curr Opin Immunol 2006, 18(5):565-570.
12. Laughlin M.J., Eapen M, Rubinstein P., Wagner J.E., Zhang M-J., Champlin R.E., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. NEngl J Med 2004, 351(22):2265-2275.
13. Rocha V., Cornish J., Sievers E.L., Filipovich A., Locatelli F., Peters C., et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001, 97(10).
14. Rocha V., Wagner J.E., Sobocinski K.A., Klein J.P., Zhang M-J., Horowitz M.M., et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. NEngl J Med 2000, 342(25):1846-1854.
15. Béziat V., Nguyen S., Lapusan S., Hervier B., Dhedin N., Bories D., et al. Fully functional NK cells after unrelated cord blood transplantation. Leukemia 2009, 23:721-728.
16. Thomson B.G., Robertson K.A., Gowan D., Heilman D., Broxmeyer H.E., Emanuel D., et al. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood 2000, 96:2703-2711.
17. Kotylo P., Baenzinger J., Yoder M., Engle W., Bolinger C. Rapid analysis of lymphocyte subsets in cord blood. Am J Clin Pathol 1990, 93(2):263-266.
18. Luevano M., Daryouzeh M., Alnabhan R., Querol S., Khakoo S., Madrigal A., et al. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol 2012, 73(3):248-257.
19. Gaddy J., Risdon G., Broxmeyer H.E. Cord Blood Natural Killer Cells Are Functionally and Phenotypically Immature but Readily Respond to Interleukin-2 and Interleukin-12. JInterferon Cytokine Res 1995, 15(6):527-536.
20. Lu X., Kondo Y., Takamatsu H., Ohata K., Yamazaki H., Takami A., et al. CD16+ CD56- NK cells in the peripheral blood of cord blood transplant recipients: a unique subset of NK cells possibly associated with graft-versus-leukemia effect. Eur J Haematol 2008 Jul, 81(1):18-25.
21. Bjorkstrom N.K., Ljunggren H.G., Sandberg J.K. CD56 negative NK cells: origin, function, and role in chronic viral disease. Trends Immunol 2010, 31(11):401-406.
22. Dalle J.-H., Menezes J., Wagner E., Blagdon M., Champagne J., Champagne M.A., et al. Characterization of Cord Blood Natural Killer Cells: Implications for Transplantation and Neonatal Infections. Pediatr Res 2005, 57(5):649-655.
23. Tanaka H., Kai S., Yamaguchi M., Misawa M., Fujimori Y., Yamamoto M., et al. Analysis of natural killer (NK) cell activity and adhesion molecules on NK cells from umbilical cord blood. Eur J Haematol 2003, 71:29-38.
24. Wang Y., Xu H., Zheng X., Wei H., Sun R., Tian Z. High Expression of NKG2A/CD94 and Low Expression of Granzyme B Are Associated with Reduced Cord Blood NK Cell Activity. Cell Mol Immunol 2007, 4(5):377-382.
25. Condiotti R., Zakaia Y.B., Barakb V., Nagler A. Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood. Exp Hematol 2001, 29:104-113.
26. Nomura A., Takada H., Jin C.-H., Tanaka T., Ohga S., Hara T. Functional analyses of cord blood natural killer cells and T cells: a distinctive interleukin-18 response. Exp Hematol 2001, 29(10):1169-1176.
27. Burgess S.J., Marusina A.I., Pathmanathan I., Borrego F., Coligan J.E. IL-21 Down-Regulates NKG2D/DAP10 Expression on Human NK and CD8+ T Cells. JImmunol 2006, 176(3):1490-1497.
28. Kasaian M.T., Whitters M.J., Carter L.L., Lowe L.D., Jussif J.M., Deng B., et al. IL-21 Limits NK Cell Responses and Promotes Antigen-Specific T Cell Activation. Immunity 2002, 16(4):559-569.
29. Perez S.A., Mahaira L.G., Sotiropoulou P.A., Gritzapis A.D., Iliopoulou E.G., Niarchos D.K., et al. Effect of IL-21 on NK cells derived from different umbilical cord blood populations. Int Immunol 2006, 18(1):49-58.
30. Cooper M.A., Elliott J.M., Keyel P.A., Yang L., Carrero J.A., Yokoyama W.M. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A 2009, 106(6):1915-1919.
31. Romee R., Schneider S.E., Leong J.W., Chase J.M., Keppel C.R., Sullivan R.P., et al. Cytokine activation induces human memory-like NK cells. Blood 2012, 120(24):4751-4760.
32. Agaugue S., Marcenaro E., Ferranti B., Moretta L., Moretta A. Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood 2008, 112(5):1776-1783.
33. Chiossone L., Vitale C., Cottalasso F., Moretti S., Azzarone B., Moretta L., et al. Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2- versus IL-15-activated NK cells. Blood 2007, 19(9):3767-3775.
34. Cooper M.A., Fehniger T.A., Turner S.C., Chen K.S., Ghaheri B.A., Ghayur T., et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood 2001, 97(10):3146-3151.
35. Gober M.D., Fishelevich R., Zhao Y., Unutmaz D., Gaspari A.A. Human Natural Killer T Cells Infiltrate into the Skin at Elicitation Sites of Allergic Contact Dermatitis. JInvest Dermatol 2007, 128(6):1460-1469.
36. Morissette M., Parent J., Milot J. Perforin, granzyme B, and FasL expression by peripheral blood T lymphocytes in emphysema. Respir Res 2007, 8(1):62.
37. Huang Y., Lei Y., Zhang H., Zhang M., Dayton A. Role of interleukin-18 in human natural killer cell is associated with interleukin-2. Mol Immunol 2010, 47(16):2604-2610.
38. Huang Y., Lei Y., Zhang H., Zhang M., Dayton A. Interleukin-12 treatment down-regulates STAT4 and induces apoptosis with increasing ROS production in human natural killer cells. JLeukoc Biol 2011, 90(1):87-97.
39. Becknell B., Caligiuri M.A. Interleukin-2, Interleukin-15, and Their Roles in Human Natural Killer Cells. Advances in Immunology 2005, 209-239. Academic Press, San Diego, CA. 10.1016/S0065-2776(04)86006-1. W.A. Frederick (Ed.).
40. Carson W.E., Giri J.G., Lindemann M.J., Linett M.L., Ahdieh M., Paxton R., et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. JExp Med 1994, 180(4):1395-1403.
41. Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol 2001, 22(11):633-640.
42. Eckelhart E., Warsch W., Zebedin E., Simma O., Stoiber D., Kolbe T., et al. Anovel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood 2011, 117(5):1565-1573.
43. Pillet A.-H., Bugault F., Thèze J., Chakrabarti L.A., Rose T. AProgrammed Switch from IL-15- to IL-2-Dependent Activation in Human NK Cells. JImmunol 2009, 182(10):6267-6277.
44. Wang R., Jaw J.J., Stutzman N.C., Zou Z., Sun P.D. Natural killer cell-produced IFN-γ and TNF-α induce target cell cytolysis through up-regulation of ICAM-1. JLeukoc Biol 2012, 91(2):299-309.
45. Romagnani S. Induction of TH1 and TH2 responses: a key role for the 'natural' immune response?. Immunol Today 1992, 13(10):379-381.
46. Kim C.H., Pelus L.M., Appelbaum E., Johanson K., Anzai N., Broxmeyer H.E. CCR7 Ligands, SLC/6Ckine/Exodus2/TCA4 and CKβ-11/MIP-3β/ELC: Are Chemoattractants for CD56+CD16-NK Cells and Late Stage Lymphoid Progenitors. Cell Immunol 1999, 193(2):226-235.
47. Martín-Fontecha A., Thomsen L.L., Brett S., Gerard C., Lipp M., Lanzavecchia A., et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for TH1 priming. Nat Immunol 2004, 5:1260-1265.
48. Sun J.C., Beilke J.N., Lanier L.L. Adaptive immune features of natural killer cells. Nature 2009, 457(7229):557-561. 10.1038/nature07665.
49. Marcoe J.P., Lim J.R., Schaubert K.L., Fodil-Cornu N., Matka M., McCubbrey A.L., et al. TGF-β is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy. Nat Immunol 2012, 13(9):843-850.
50. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006, 6(8):595-601. 10.1038/nri1901.
51. Lécine P., Algarté M., Rameil P., Beadling C., Bucher P., Nabholz M., et al. Elf-1 and Stat5 bind to a critical element in a new enhancer of the human interleukin-2 receptor alpha gene. Mol Cell Biol 1996, 16(12):6829-6840.
52. Fehniger T.A., Shah M.H., Turner M.J., VanDeusen J.B., Whitman S.P., Cooper M.A., et al. Differential Cytokine and Chemokine Gene Expression by Human NK Cells Following Activation with IL-18 or IL-15 in Combination with IL-12: Implications for the Innate Immune Response. JImmunol 1999, 162:4511-4520.
53. Satwani P., van de Ven C., Ayello J., Cairo D., Simpson L.L., Baxi L., et al. Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 significantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function. Cytotherapy 2011, 13(6):730-738.
54. Kim S., Poursine-Laurent J., Truscott S.M., Lybarger L., Song Y.-J., Yang L., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436(7051):709-713. 10.1038/nature03847.
55. Frey M., Packianathan N.B., Fehniger T.A., Ross M.E., Wang W.-C., Stewart C.C., et al. Differential Expression and Function of L-Selectin on CD56bright and CD56dim Natural Killer Cell Subsets. JImmunol 1998, 161(1):400-408.
56. Campbell J.J., Qin S., Unutmaz D., Soler D., Murphy K.E., Hodge M.R., et al. Unique Subpopulations of CD56+ NK and NK-T Peripheral Blood Lymphocytes Identified by Chemokine Receptor Expression Repertoire. JImmunol 2001, 166(11):6477-6482.
57. Inngjerdingen M., Damaj B., Maghazachi A.A. Expression and regulation of chemokine receptors in human natural killer cells. Blood 2001, 97(2):367-375.
58. Marcenaro E., Cantoni C., Pesce S., Prato C., Pende D., Agaugue S., et al. Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction. Blood 2009, 114(19):4108-4116.
59. Marcenaro E., Pesce S., Sivori S., Carlomagno S., Moretta L., Moretta A. KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DCs or T-cell blasts. Blood 2013, 121(17):3396-3401.
60. Parolini S., Santoro A., Marcenaro E., Luini W., Massardi L., Facchetti F., et al. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood 2007, 109(9):3625-3632.
61. Shah N., Martin-Antonio B., Yang H., Ku S., Lee D.A., Cooper L.J.N., et al. Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. PLoS One 2013, 8(10):e76781.
62. Xing D., Ramsay A.G., Gribben J.G., Decker W.K., Burks J.K., Munsell M., et al. Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. JImmunother 2010, 33(7):684-696.
63. Geller M.A., Cooley S., Judson P.L., Ghebre R., Carson L.F., Argenta P.A., et al. Aphase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011, 13(1):98-107.
64. Ni J., Miller M., Stojanovic A., Garbi N., Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. JExp Med 2012, 209(13):2351-2365.